LYTIR

Company · BMRN

BioMarin Pharmaceutical Inc.

Name as listed on its exchange; filed with the SEC as BIOMARIN PHARMACEUTICAL INC.

Nasdaq's symbol directory lists BMRN on Nasdaq as “BioMarin Pharmaceutical Inc. - Common Stock”.

In the 12 months to Nov 19, 2026: insiders sold on 1 occasion ($1.2M); 1 filing by holders of 5% or more; 5 company reports (Form 8-K, since May 26, 2026).

All insider filings at the SEC · Appeared in No. 8

Insider trades · SEC Form 4

Those inside the hall

Open-market purchases and sales only. Legs one person filed for one day are combined.

Who traded

  1. Davis George Eric, EVP, Chief Legal Officer sold on 1 day latest Sep 2, 2026 sold $1.2M
Every trade (1)
  1. SELLDavis George Eric, EVP, Chief Legal Officer sold Sep 2, 2026 17,557 shares filing $1.2M

Large holders · SEC Schedules 13D and 13G

Five percent and over

Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G

  1. BlackRock, Inc. filed Nov 4, 2026 Schedule 13G/A passive 19,373,309 shares filing 10%

Executive branch · OGE Form 278-T

Reported by the President

1 confirmed trade on scanned reports whose security name matches this company's own filed name exactly (letter case, punctuation and Inc/Corp-style endings aside). All of Donald J. Trump's reports

  1. Purchase: BIOMARIN PHARMACEUTICAL Apr 17, 2026 reported Jun 25, 2026 President Donald J. Trump Periodic Transaction Report 06.25.26 (1) $1,001 – $15,000

Company reports · SEC Form 8-K

In its own words

Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.

  1. Results of operations and financial condition filing Nov 2, 2026
  2. Results of operations and financial condition filing Oct 6, 2026
  3. Entry into a material definitive agreement filing Sep 30, 2026
  4. Other events filing Sep 15, 2026
  5. Departure or appointment of directors or officers filing Sep 14, 2026

Sources: SEC EDGAR (Forms 4, 144 and 8-K), OGE Form 278-T reports on whitehouse.gov and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.